Piper Jaffray analyst JP McKim says his latest channel checks on DexCom (DXCM) show that supply is still constrained but getting better. Further, the checks indicate that Abbott's (ABT) Libre 14 day sensor is the same price as the 10 day on a per day basis and should be launching in the next month, McKim tells investors in a research note. While it is "too soon to blow the all clear horn" on DexCom's supply issues, things are "improving steadily" and the demand for the company's G6 remains robust, the analyst contends. He believes the continuous glucose monitoring market is "really taking off" and expects continued strong results from DexCom in both Q3 and Q4. McKim keeps an Overweight rating on the shares with a $150 price target.